Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application

Abstract

Abstract:

Objective:To identify the differentially expressed genes of phosphatidylinositide3-kinase(PI3K), nuclear factor kappa-B(NF-κB) and RAS/RAF signal pathways at mRNA and protein levels in pediatric Burkitt lymphoma（BL） for exploring the correlation of these genes with the development and progression of BL and determining the specific target genes for diagnosis and treatment monitoring.Methods:Tumor tissues from 18 cases of pediatric BL and tissues of normal lymphnodes of 20 pediatric cases were collected. The expression levels of mRNA of related target genes in the pathways were analyzed by real-time fluorescence quantitative reverse transcription polymerase chain reaction and the protein levels were determined by immunohistochemistry.Results:The expressions ofMYC, TCF3, ID3, CCDN3, CDK6, CDK4, NRAS, RAF1at mRNA and protein levels were up-expressed significantly in BL and some target genes and its protein of NF-κB pathway such asBCL2, CD44, C-FLIP, CCND2andA20were suppressed in BL when compared with normal tissues (P<0.05). Cases carrying c-MYC translocation and BCL2 expression (BCL2⁺) had higher serum LDH levels (P<0.05).Conclusions:Expressions ofMYC, TCF3, CCND3, CDK6, NRASandRAF1genes are high,which might be used as molecular markers for the diagnosis and treatment monitoring of pediatric BL.c-MYCgene translocation accompanied with BCL2⁺might be an important molecular indicator in BL, which is correlated with high serum LDH level, indicating advanced tumor staging, high tumor burden, and poor prognosis.

Key words:Pediatric Burkitt lymphoma,Clinical molecular target,Fluorescence quantitative reverse transcription polymerase chain reaction,Immunohistochemistry

CLC Number:

R733.4

MENG Leijun, ZHANG Jing, WANG Xueli, LI Zhi, ZHANG Hong, ZENG Naiyan. Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application[J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 248-257.

Figures/Tables13

基因	引物	序列（5'→3'）	扩增子长度(bp)
MYC	正向反向	TAGTGGAAAACCAGCAGCCT GTCGCAGTAGAAATACGGCTG	107
TCF3	正向反向	AAGCACTGGCCTCGATCTACTC GAGGCCACTGTGACGTTCCT	111
ID3	正向反向	ATCCAGACAGCCGAGCTCAC GCGTTCTGGAGGTGTCAGGA	96
CCND3	正向反向	CAGTGCAAGGCCTGGGTG CTGAGTGCAGCTTCGATCTGCT	124
CDKN2A	正向反向	TGCCCAACGCACCGAATA CACGGGTCGGGTGAGAGTG	137
CKD6	正向反向	AAATCTTGGACGTGATTGGACTC AACACTTCAGAAGTAGGTCTTTGCCTA	153
CDK4	正向反向	ACACCCGTGGTTGTTACACTCT ACAGAAGAGAGGCTTTCGACG	132
TP53	正向反向	GTGTGGTGGTGCCCTATG CAGTGTGATGATGGTGAGGAT	128
PTEN	正向反向	TTGCAGAGTTGCACAATATCCT TCTTCACTTAGCCATTGGTCAAG	99
PTPN6	正向反向	GGAGGAGTTTGAGAGTTTGCAGA GCTGTGGTCAAAGGGGAGAA	121
A20	正向反向	AGGTTCCAGAACACCATTCC GGCTCGATCTCAGTTGCTC	151
ABIN-1	正向反向	GAAGCAAGTGGAGAAGCTGC CTCTCCTGAGGCCTTTGCT	127
ABIN-2	正向反向	GCAGATTCTCGCTTACAAGGA TCCTGTCTCCAGGACACCT	126
ABIN3	正向反向	CGCATCAGAGGCAGAGAAAGG TTCCTTCTCCTCCCGCTGC	92
BCL2	正向反向	GATAACGGAGGCTGGGATG AGCCAGGAGAAATCAAACAGAG	74
CCND2	正向反向	CTGGCCTCCAAACTCAAAGAG GCACCACCAGTTCCCACTC	109
CD44	正向反向	CAGCTCCACCTGAAGAAGATTG GGTGCCATCACGGTTAACAA	95
C-FLIP	正向反向	GACCTGCTCAAACGTATCTTGAAG CTCTGCCATCAGCACTCTATAGTC	102
IRF4	正向反向	CTTTGAGGAACTGGTTGAGCG GCTGCTTGGCTCCTTTTTTG	98
CCR2A	正向反向	GCGTTTAATCACATTCGAGTGTTT CCACTGGCAAATTAGGGAACAA	77
CD69	正向反向	CCACCAGTCCCCATTTCTCAA TTGGCCCACTGATAAGGCAAT	125
TLR6	正向反向	AACAAGTACCACAAGCTGAAG CTCTAATGTTAGCCCAAAAGAG	100
IκBɑ	正向反向	CTGAAGGCTACCAACTACAATGG CACCAAAAGCTCCACGATG	84
KRAS	正向反向	TGAGGGACCAGTACATGAGGA CCTACTAGGACCATAGGTACATCTTCAG	145
NRAS	正向反向	AGCTTGAGGTTCTTGCTGGTGT CAAAGTGGTTCTGGATTAGCTGGAT	110
RAF1	正向反向	AGAACAGTGGTCAATGTGCGA TTTACCTTTGTGTTCGTGGAGAAG	126
18S	正向反向	TGACTCAACACGGGAAACC TCGCTCCACCAACTAAGAAC	114

名称	品牌	货号	稀释比例	抗原修复
ID3	Abcam,美国	ab2365045	1∶50	pH=6.0
TCF3	Abcam,美国	ab69999	1∶50	pH=9.0
CFLAR/C-FLIP	Proteintech,日本	10394-1-AP	1∶50	pH=6.0
BCL2	Proteintech,日本	12789-1-AP	1∶00	pH=9.0
CD44	Proteintech,日本	15675-1-AP	1∶200	pH=9.0
CDK6	Proteintech,日本	19117-1-AP	1∶200	pH=9.0
MYC	Proteintech,日本	10828-1-AP	1∶200	pH=6.0
RAF1	Proteintech,日本	51140-1-AP	1∶50	pH=6.0
CDK4	Proteintech,日本	11026-1-AP	1∶300	pH=9.0
NRAS	Proteintech,日本	10724-1-AP	1∶200	pH=9.0
Cyclin D3	Proteintech,日本	26755-1-AP	1∶200	pH=6.0
SHP1	Proteintech,日本	24546-1-AP	1∶200	pH=9.0
TNFAIP3 A	Bioss,中国	bs-2803R	1∶200	pH=6.0
Anti-Cyclin D2	Bioss,中国	bs-1148R	1∶200	pH=6.0

序号	年龄（岁）	性别	发病部位	分期	骨髓	中枢神经系统	预后	c-MYC基因易位	肿瘤溶解综合征
1	3	男	颈部	Ⅱ	未累及	未累及	良好	+	未发生
2	11	男	鼻咽部	Ⅲ	未累及	未累及	良好	-	未发生
3	4	男	鼻咽部	Ⅲ	未累及	未累及	不良	+	未发生
4	10	女	回盲部	Ⅲ	未累及	未累及	良好	-	未发生
5	4	男	十二指肠	Ⅲ	未累及	未累及	良好	+	未发生
6	5	男	鼻咽部	Ⅱ	未累及	未累及	良好	-	未发生
7	7	女	卵巢	Ⅲ	未累及	未累及	良好	-	未发生
8	5	男	腹股沟	Ⅲ	未累及	未累及	良好	+	发生
9	1	女	腹股沟	Ⅲ	未累及	未累及	良好	+	未发生
10	4	男	腹腔	Ⅲ	未累及	未累及	良好	+	未发生
11	6	男	椎管内	Ⅲ	未累及	未累及	良好	-	未发生
12	6	男	肺部	Ⅳ	累及	未累及	不良	+	未发生
13	9	男	回盲部	Ⅲ	未累及	未累及	良好	+	未发生
14	10	男	结肠	Ⅲ	未累及	未累及	不良	+	未发生
15	10	男	结肠	Ⅲ	未累及	未累及	良好	+	未发生
16	6	男	颈部	Ⅱ	未累及	未累及	良好	+	未发生
17	2	男	回盲部	Ⅳ	累及	未累及	不良	+	未发生
18	2	男	回盲部	Ⅲ	未累及	未累及	/	+	未发生

相关基因	P值
MYC^*	0.015
TCF3^*	0.007
ID3^*	0.017
CCND3^*	0.048
CDK6^*	0.001
CDK4^*	0.039
PTPN6^#	0.043
CDKN2A	0.845
PTEN	0.755
TP53	0.743

相关基因	P值
A20^#	0.016
BCL2^#	0.003
CCND2^#	0.001
C-FLIP^#	0.030
CD44^#	0.029
IRF4	0.467
ABIN1	0.531
ABIN2	0.134
ABIN3	0.873
CD69	0.157
CCR2A	0.955
IκB-ɑ	0.363
TLR6	0.614

相关基因	P值
KRAS	0.653
NRAS	0.005
RAF1	0.013

临床特征及指标	c-MYC⁺伴BCL2⁺	c-MYC^+/-伴BCL2^+/-	P值
性别
男	5	10	0.485
女	1	2
分期
Ⅰ或Ⅱ	0	3	0.270
Ⅲ或Ⅳ	6	9
预后
良好	3	10	0.091
不良	3	1
LDH
升高	5	3	0.030
正常	1	9
UA
升高	4	3	0.264
正常	4	7
其他
LDH和UA均升高	4	1	0.022
LDH或UA任意一个指标升高或均正常	2	11

临床特征及指标	BCL2
临床特征及指标	+	-	P值
性别
男	5	7	0.462
女	1	0
分期
Ⅰ或Ⅱ	0	2	0.269
Ⅲ或Ⅳ	6	5
预后
良好	3	5	0.242
不良	3	1
LDH
>正常水平	5	1	0.025
正常水平	1	6
UA
>正常	4	3	0.306
正常	2	4
其他
LDH和UA 均升高	4	1	0.082
LDH或UA任意一个指标升高或均正常	2	6

References23

[1]	Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead[J]. J Clin Oncol, 2015, 33(27):2963-2974. doi:10.1200/JCO.2014.59.5827pmid:26304908
[2]	Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma[J]. N Engl J Med, 2006, 354(23):2431-2442. doi:10.1056/NEJMoa055759 URL
[3]	Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling[J]. N Engl J Med, 2006, 354(23):2419-2430. doi:10.1056/NEJMoa055351 URL
[4]	Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma[J]. Lancet, 2012, 379(9822):1234-1244. doi:10.1016/S0140-6736(11)61177-X URL
[5]	Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomage-nesis[J]. Cancer Cell, 2012, 22(2):167-179. doi:10.1016/j.ccr.2012.06.012 URL
[6]	Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics[J]. Nature, 2012, 490(7418):116-120. doi:10.1038/nature11378 URL
[7]	Gramling MW, Eischen CM. Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis[J]. Cell Death Differ, 2012, 19(7):1220-1227. doi:10.1038/cdd.2012.1pmid:22301919
[8]	Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives[J]. Pediatr Hematol Oncol, 2013, 30(6):465-483. doi:10.3109/08880018.2013.783891 URL
[9]	张梦, 金玲, 杨菁, 等. 儿童伯基特淋巴瘤186例临床特征及疗效分析[J]. 中华儿科杂志, 2018, 56(8):605-610.
[10]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390. doi:10.1182/blood-2016-01-643569pmid:26980727
[11]	Pitkin L, Luangdilok S, Corbishley C, et al. Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival[J]. Br J Cancer, 2007, 97(5):670-677. doi:10.1038/sj.bjc.6603907 URL
[12]	Lee S, Day NS, Miles RR, et al. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report[J]. Br J Haematol, 2017, 177(4):601-611. doi:10.1111/bjh.14604 URL
[13]	Cai Q, Medeiros LJ, Xu X, et al. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management[J]. Oncotarget, 2015, 6(36):38591-38616. doi:10.18632/oncotarget.5774 URL
[14]	Greenough A, Dave SS. New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing[J]. Curr Opin Hematol, 2014, 21(4):326-332. doi:10.1097/MOH.0000000000000059pmid:24867287
[15]	Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma[J]. Nat Genet, 2012, 44(12):1321-1325. doi:10.1038/ng.2468 URL
[16]	魏洁, 范林妮, 李侠, 等. 中国人Burkitt淋巴瘤中ID3、TCF3及MYC基因突变分析[J]. 临床试验与病理学杂志, 2016, 32(12):1343-1347.
[17]	Cornall RJ, Cyster JG, Hibbs ML, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection[J]. Immunity, 1998, 8(4):497-508. pmid:9586639
[18]	Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm[J]. Nat Rev Cancer, 2009, 9(3):153-166. doi:10.1038/nrc2602pmid:19238148
[19]	Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma[J]. Pathology. 2018 Jan; 50(1):74-87. doi:10.1016/j.pathol.2017.09.006 URL
[20]	Yoshida M, Ichikawa A, Miyoshi H, et al. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma[J]. Pathol Int, 2015, 65(9):486-489. doi:10.1111/pin.12333pmid:26182827
[21]	Strasser A, Harris AW, Bath ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by coopera-tion between myc and Bcl-2[J]. Nature, 1990, 348(6299):331-333. doi:10.1038/348331a0 URL
[22]	杨文萍, 黄慧, 宫丽平, 等. 儿童散发性伯基特淋巴瘤的分子遗传学特征分析[J]. 中华病理学杂志, 2010, 39(12):819-824.
[23]	Criscuolo M, Fianchi L, Dragonetti G, et al. Tumor lysis syndrome: review of pathogenesis, risk factors and mana-gement of a medical emergency[J]. Expert Rev Hematol, 2016, 9(2):197-208. doi:10.1586/17474086.2016.1127156pmid:26629730